URTESTE S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 98 PLN | +0.20% |
|
+2.08% | -10.09% |
| 2021 | Urteste S.A. has completed an IPO in the amount of PLN 9.52 million. | CI |
| 2021 | Urteste S.A. has filed an IPO. | CI |
| Sales 2020 | - | Sales 2021 | - | Capitalization | 109M 439M 9.12B |
|---|---|---|---|---|---|
| Net income 2020 | -1M -4.01M -83.36M | Net income 2021 | -2M -8.03M -167M | EV / Sales 2020 * | - |
| Net cash position 2020 | 427K 1.72M 35.62M | Net cash position 2021 | 8.53M 34.25M 711M | EV / Sales 2021 | - |
| P/E ratio 2020 * |
-
| P/E ratio 2021 |
-47.1
x | Employees | 1 |
| Yield 2020 * |
-
| Yield 2021 |
-
| Free-Float | 27.21% |
More Fundamentals
* Assessed data
| 1 day | +0.20% | ||
| 1 week | +2.08% | ||
| Current month | +0.20% | ||
| 1 month | +4.48% | ||
| 3 months | -3.92% | ||
| 6 months | -6.67% | ||
| Current year | -10.09% |
1 week
92.00
98.00
1 month
92.00112.50
Current year
85.00112.50
1 year
81.00138.00
3 years
70.40191.00
5 years
70.40191.00
10 years
70.40191.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 54 | 16/21/16 | |
| Corporate Officer/Principal | 54 | 16/21/16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 57 | 29/22/29 | |
Slawomir Kosciak
BRD | Director/Board Member | 40 | 26/21/26 |
| Director/Board Member | 45 | 26/21/26 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/24/02 | 98 | +0.20% | 22 |
| 30/24/30 | 97.8 | 0.00% | 2 |
| 29/24/29 | 97.8 | +1.87% | 395 |
| 26/24/26 | 96 | 0.00% | 22 |
| 25/24/25 | 96 | 0.00% | 123 |
Delayed Quote Warsaw S.E., May 02, 2024 at 09:25 pm IST
More quotes
Urteste SA is a Poland-based company mainly engaged in the biotechnology sector. The Company operates in the field of medical devices for in vitro application in the field of cancer diagnostics. The technology developed by the Company involves the detection of cancer by measuring the activity of enzymes in a urine sample, using diagnostic tests that enable the detection of common cancers in their early stages. The Company offers tests for the detection of cancers such as, pancreatic cancer, prostate cancer, colorectal cancer, lung cancer, kidney cancer, liver cancer, biliary tract cancer, stomach cancer, esophageal cancer, ovarian cancer, endometrial cancer, breast cancer, leukemia, lymphoma, glioma.
| 1st Jan change | Capi. | |
|---|---|---|
| -10.09% | 34.11M | |
| +25.69% | 48.09B | |
| +46.90% | 40.62B | |
| -3.46% | 40.43B | |
| -6.20% | 28.36B | |
| +9.17% | 24.89B | |
| -20.42% | 19.01B | |
| +28.07% | 12.09B | |
| +0.17% | 11.88B | |
| -1.24% | 11.8B |
- Stock Market
- Equities
- URT Stock
